LLY · News · 20260808N

Market Demand - Anti-Obesity

ELI LILLY & Co · 2026-08-08 · Importance 68 · Surprise 56

Eli Lilly reported continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND in the second quarter of 2026. The products drove the company’s reported 48% year-over-year revenue growth, indicating strong demand across diabetes and obesity treatment markets. Demand for MOUNJARO and ZEPBOUND remains the primary market growth driver identified in the report.

Key facts